Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common StockGlobeNewsWire • 02/18/21
Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common StockGlobeNewsWire • 02/16/21
Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform TechnologyGlobeNewsWire • 02/10/21
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002GlobeNewsWire • 11/19/20
Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/13/20
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020GlobeNewsWire • 11/06/20
Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of CancersGlobeNewsWire • 10/22/20
Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/09/20
Bio-Path Holdings Inc (BPTH) CEO Peter Nielsen on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/14/20
Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid LeukemiaGlobeNewsWire • 08/13/20
Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020GlobeNewsWire • 08/07/20
Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/15/20